The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Targeting CDK2 in cancer: challenges and opportunities for therapy
Abstract
Cyclin-dependent kinase 2 (CDK2) plays a pivotal part in cell cycle regulation and is involved in a range of biological processes. CDK2 interacts with and phosphorylates proteins in pathways such as DNA damage, intracellular transport, protein degradation, signal transduction, DNA and RNA metabolism and translation. CDK2 and its regulatory subunits are deregulated in many human cancers and there is emerging evidence suggesting CDK2 inhibition elicits antitumor activity in a subset of tumors with defined genetic features. Previous CDK2 inhibitors were nonspecific and limited by off-target effects. The development of new-generation CDK2 inhibitors represents a therapeutic opportunity for CDK2-dependent cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Rapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
Cyclin-dependent kinases regulate the antiproliferative function of Smads
Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F. (2004) · Nature · doi:10.1038/nature02650 · Cited by 503
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Chen, L., Nievera, C. J., Lee, A. Y.-L., & Wu, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710245200 · Cited by 424
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Choudhary, G. S., Al-harbi, S., Mazumder, S., Hill, B. T., Smith, M. R., Bodo, J., Hsi, E. D., & Almasan, A. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.525 · Cited by 390
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B. M., et al. (2014) · Nature · doi:10.1038/nature13079 · Cited by 361
CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage
Huang, H., Regan, K. M., Lou, Z., Chen, J., & Tindall, D. J. (2006) · Science · doi:10.1126/science.1130512 · Cited by 336
Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells
Matsumoto, Y., Hayashi, K., & Nishida, E. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80191-2 · Cited by 330
Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts.
Pagano, M., Pepperkok, R., Lukas, J., Baldin, V, Ansorge, W., Bartek, J., & Draetta, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.1.101 · Cited by 322
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., & Huang, H. (2010) · Nature Cell Biology · doi:10.1038/ncb2116 · Cited by 281
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Self-citationCdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner, S., Doni, M., Hydbring, P., Verrecchia, A., Bianchi, L., Sardella, D., Schleker, T., Perna, D., Tronnersjö, S., Murga, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2004 · Cited by 251
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Rogatsky, I., Trowbridge, J. M., & Garabedian, M. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22296 · Cited by 205
Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis
Maddika, S., Ande, S. R., Wiechec, E., Hansen, L. L., Wesselborg, S., & Los, M. (2008) · Journal of Cell Science · doi:10.1242/jcs.009530 · Cited by 193
Sur, S., & Agrawal, D. K. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2693-2 · Cited by 190
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167
p21 Inhibits Cdk1 in the Absence of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint
Satyanarayana, A., Hilton, M. B., & Kaldis, P. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-06-0525 · Cited by 167
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, C., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 163
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
Self-citationCaldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A. M., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 159
Self-citationMre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2
Buis, J. M., Stoneham, T., Spehalski, E. I., & Ferguson, D. O. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2212 · Cited by 151
Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer
Caldon, C. E., & Musgrove, E. A. (2010) · Cell Division · doi:10.1186/1747-1028-5-2 · Cited by 150
Self-citationLange, C. A., & Yee, D. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0112 · Cited by 148
Pierson-Mullany, L. K., & Lange, C. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10542-10557.2004 · Cited by 140
CDK targeting of NBS1 promotes DNA‐end resection, replication restart and homologous recombination
Falck, J., Forment, J. V., Coates, J., Mistrík, M., Lukas, J., Bártek, J., & Jackson, S. P. (2012) · EMBO Reports · doi:10.1038/embor.2012.58 · Cited by 135
Deans, A. J., Khanna, K. K., McNees, C. J., Mercurio, C., Heierhorst, J., & McArthur, G. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3945 · Cited by 130
The Cyclin A1-CDK2 Complex Regulates DNA Double-Strand Break Repair
Müller‐Tidow, C., Ji, P., Diederichs, S., Potratz, J. C., Bäumer, N., Köhler, G., Cauvet, T., Choudary, C., van der Meer, T., Chan, W. Y. I., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8917-8928.2004 · Cited by 121
Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2*
Morawski, P. A., Mehra, P., Chen, C., Bhatti, T. R., & Wells, A. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467704 · Cited by 120
Mukherjee, S., & Conrad, S. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502278200 · Cited by 120
Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813139 · Cited by 108
Sonntag, R., Giebeler, N., Nevzorova, Y. A., Bangen, J., Fahrenkamp, D., Lambertz, D., Haas, U., Hu, W., Gaßler, N., Cubero, F. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807155115 · Cited by 107
Patel, H., Abduljabbar, R. F., Lai, C., Periyasamy, M., Harrod, A., Gemma, C., Steel, J. H., Patel, N. R., Busonero, C., Jerjees, D. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1104 · Cited by 106
Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1
Keck, J. M., Summers, M. K., Tedesco, D., Ekholm‐Reed, S., Chuang, L.-C., Jackson, P. K., & Reed, S. I. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703202 · Cited by 103
Adon, A. M., Zeng, X., Harrison, M. K., Sannem, S., Kiyokawa, H., Kaldis, P., & Saavedra, H. I. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-09 · Cited by 101
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Yang, L., Fang, D., Chen, H., Lu, Y.-Y., Dong, Z., Ding, H., Jing, Q., Su, S., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4600 · Cited by 100
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
Wang, J., Yang, T., Xu, G., Liu, H., Ren, C., Xie, W., & Wang, M. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.007 · Cited by 94
Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation
Merrick, K. A., Wohlbold, L., Zhang, C., Allen, J. J., Horiuchi, D., Huskey, N. E., Goga, A., Shokat, K. M., & Fisher, R. P. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.031 · Cited by 91
Takada, M., Zhang, W., Suzuki, A., Kuroda, T. S., Yu, Z., Inuzuka, H., Gao, D., Wan, L., Zhuang, M., Hu, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1240 · Cited by 90
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 88
Horiuchi, D., Huskey, N. E., Kusdra, L., Wohlbold, L., Merrick, K. A., Zhang, C., Creasman, K. J., Shokat, K. M., Fisher, R. P., & Goga, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111317109 · Cited by 87
Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance
Chunder, N., Wang, L., Chen, C., Hancock, W. W., & Wells, A. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202313 · Cited by 84
Cyclin E Deregulation Promotes Loss of Specific Genomic Regions
Teixeira, L. K., Wang, X., Li, Y., Ekholm‐Reed, S., Wu, X., Wang, P., & Reed, S. I. (2015) · Current Biology · doi:10.1016/j.cub.2015.03.022 · Cited by 83
New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation
Wells, A. D., & Morawski, P. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3625 · Cited by 83
Phosphorylation of Mcm2 by Cdc7 Promotes Pre-replication Complex Assembly during Cell-Cycle Re-entry
Chuang, L.-C., Teixeira, L. K., Wohlschlegel, J. A., Henze, M., Yates, J. R., Méndez, J., & Reed, S. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.014 · Cited by 80
Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer
Caldon, C. E., Sutherland, R. L., & Musgrove, E. A. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11474 · Cited by 78
Self-citationPatel, P. M., Tsiperson, V., Gottesman, S. R. S., Somma, J., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0602 · Cited by 76
Wohlbold, L., Merrick, K. A., De, S., Amat, R., Kim, J. H., Larochelle, S., Allen, J. J., Zhang, C., Shokat, K. M., Petrini, J. H. J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002935 · Cited by 71
Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc
Caldon, C. E., Sergio, C. M., Schütte, J., Boersma, M. N., Sutherland, R. L., Carroll, J. S., & Musgrove, E. A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00269-09 · Cited by 71
Self-citationTargeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi, A., Caramuta, S., Seashore-Ludlow, B. A., Boström, J., Robinson, J. L., Edfors, F., Tuominen, R., Kemper, K., Krijgsman, O., Peeper, D. S., et al. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177858 · Cited by 71
Choudhary, G. S., Tat, T. T., Misra, S., Hill, B. T., Smith, M. R., Almasan, A., & Mazumder, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4857 · Cited by 67
Beale, G., Haagensen, E. J., Thomas, H. D., Wang, L.-Z., Revill, C., Payne, S. L., Golding, B. T., Hardcastle, I. R., Newell, D. R., Griffin, R. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.238 · Cited by 66
Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice
Bangen, J., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., Longerich, T., Lammers, T., Tacke, F., Trautwein, C., et al. (2017) · Hepatology · doi:10.1002/hep.29275 · Cited by 63
Musgrove, E. A., Hunter, L.-J. K., Lee, C. S. L., Swarbrick, A., Hui, R., & Sutherland, R. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106371200 · Cited by 59
Identification of CDK2 as a Novel Target in Treatment of Prostate Cancer
Yin, X., Yu, J. J., Zhou, Y., Wang, C., Jiao, Z., Qian, Z., Sun, H. X., & Chen, B. (2018) · Future Oncology · doi:10.2217/fon-2017-0561 · Cited by 57
CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110
Hu, S., Danilov, A. V., Godek, K. M., Orr, B., Tafe, L. J., Rodriguez‐Canales, J., Behrens, C., Mino, B., Moran, C. A., Memoli, V. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1494 · Cited by 54
Opyrchal, M., Salisbury, J. L., Iankov, I. D., Goetz, M. P., McCubrey, J. A., Gambino, M. W., Malatino, L., Puccia, G., Ingle, J. N., Galanis, E., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2523 · Cited by 53
Cocco, E., Lopez, S., Black, J., Bellone, S., Bonazzoli, E., Predolini, F., Ferrari, F., Schwab, C. L., Menderes, G., Zammataro, L. A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.198 · Cited by 50
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer
Kawakami, M., Mustachio, L. M., Rodriguez‐Canales, J., Mino, B., Roszik, J., Tong, P., Wang, J., Lee, J. J., Myung, J. H., Heymach, J. V., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw297 · Cited by 50
Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma
Cheng, C. K., Gustafson, W. C., Charron, E. M., Houseman, B. T., Zunder, E. R., Goga, A., Gray, N. S., Pollok, B. A., Oakes, S. A., James, C. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202492109 · Cited by 48
Alexander, A., Karakaş, C., Chen, X., Carey, J. P. W., Yi, M., Bondy, M. L., Thompson, P. A., Cheung, K., Ellis, I. O., Gong, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14689 · Cited by 48
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Rao, S. S., Stoehr, J. R., Đokić, D., Wan, L., Decker, J. T., Konopka, K. E., Thomas, A. L., Wu, J., Kaklamani, V., Shea, L. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20202 · Cited by 47
Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas
Faber, A. C., & Chiles, T. C. (2007) · Cell Cycle · doi:10.4161/cc.6.23.4994 · Cited by 46
Aziz, D., Etemadmoghadam, D., Caldon, C. E., Au‐Yeung, G., Deng, N., Hutchinson, R. A., Bowtell, D. D. L., & Waring, P. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.039 · Cited by 44
Self-citationHOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2
LI, Y., YANG, X. H., FANG, S. J., QIN, C. F., Sun, R., LIU, Z. Y., JIANG, B. Y., Wu, X., & Li, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3668 · Cited by 42
CDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
Varma, H., Skildum, A. J., & Conrad, S. E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001256 · Cited by 30
CDK2 and FOXO1: A Fork in the Road for Cell Fate Decisions
Huang, H., & Tindall, D. J. (2007) · Cell Cycle · doi:10.4161/cc.6.8.4122 · Cited by 25 · cited 1×
“…allows FOXO1 to become transcriptionally active [23] and trigger apoptosis via upregulation of numerous proapoptotic proteins such as Fas ligand (FasL), Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and B-cell lymphoma 2 (BCL-2) interacting mediator of cell death (Bim) [24].”
Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers
Kawakami, M., Mustachio, L. M., Liu, X., & Dmitrovsky, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1108 · Cited by 21
Jorda, R., Bučková, Z., Řezníčková, E., Bouchal, J., & Kryštof, V. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.11.011 · Cited by 19
Davis, R. J., Swanger, J., Hughes, B. T., & Clurman, B. E. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00657-16 · Cited by 15
Cited by
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 372
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability
Fagundes, R., & Teixeira, L. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774845 · Cited by 276
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0391 · Cited by 168
Pogacar, Z., Johnson, J. L., Krenning, L., De Conti, G., Jochems, F., Lieftink, C., Velds, A., Wardak, L., Groot, K., Schepers, A., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0273182 · Cited by 13
Metadata
- Authors
- Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 25
- Issue
- 2
- Pages
- 406-413
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2996617366
- Cited by
- 333
- References
- 79
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.